[Side effects of chemotherapy for testicular cancers and post-cancer follow-up].

Effets secondaires de la chimiothérapie des cancers testiculaires et suivi de l’après cancer.

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 22 06 2018
revised: 15 04 2019
accepted: 15 04 2019
pubmed: 7 6 2019
medline: 19 9 2019
entrez: 8 6 2019
Statut: ppublish

Résumé

Testicular cancers are the most frequent and the most curable cancers in young men. Treatments of these cancers represent a great success with cure rate over to 95 %. However, chemotherapy side effects may occur during or after several years post-treatment. This review aimed to highlight complications and physical and psychological side effects occurring mainly after chemotherapy treatment for testicular cancer, and to propose a personalized post-cancer plan specific for patients treated for testicular cancer. Treatments of these cancers can cause short-term complications (asthenia, nausea, vomiting, alopecia..). These side effects disappear within a few months after the end of the treatments. Late complications may occur several years post-treatment. Cardiovascular disease, metabolic syndrome and secondary neoplasia represent the most severe late effects among patients treated for testicular cancer. Given the increased incidence of these chemotherapy-induced side effects, it is indispensable to establish a specific follow up which must include a particular vigilance on the risk of occurrence of second cancer, a follow-up of the cardio-vascular risk factors, pulmonary and auditory follow-up, and early detection of psychosocial disorders.

Identifiants

pubmed: 31171345
pii: S0007-4551(19)30195-X
doi: 10.1016/j.bulcan.2019.04.004
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

805-811

Informations de copyright

Copyright © 2019. Published by Elsevier Masson SAS.

Auteurs

Florence Joly (F)

UNICANCER, Centre François Baclesse, Clinical Research Department and Medical Department, avenue général Harris, 14076 Caen, France; Inserm, U1086, 14076 Caen, France; Université de Caen Basse-Normandie, UMR-S1077, 14000 Caen, France; CHU de Caen, Department of Oncology, 14000 Caen, France. Electronic address: f.joly@baclesse.unicancer.fr.

Djihane Ahmed-Lecheheb (D)

UNICANCER, Centre François Baclesse, Clinical Research Department and Medical Department, avenue général Harris, 14076 Caen, France; Inserm, U1086, 14076 Caen, France.

Antoine Thiery-Vuillemin (A)

CHU Jean-Minjoz, Département Oncologie médicale, Boulevard Fleming, 25030 Besançon, France.

Emeline Orillard (E)

CHU Jean-Minjoz, Département Oncologie médicale, Boulevard Fleming, 25030 Besançon, France.

Elodie Coquan (E)

UNICANCER, Centre François Baclesse, Clinical Research Department and Medical Department, avenue général Harris, 14076 Caen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH